Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned

A 66-year-old woman with a history of stage IA mixed endometrioid and serous endometrial cancer presented to our centre with 2 weeks of worsening headaches nearly 4 years after her initial surgery. At admission, she manifested bitemporal hemianopsia, difficulty walking and clinical and laboratory findings of panhypopituitarism, including diabetes insipidus. Magnetic resonance imaging of the brain revealed a 2.7 cm sellar/suprasellar mass compressing the optic chiasm and infiltrating the pituitary stalk. Computerised tomography documented mediastinal, lung, adrenal and liver involvement, including a 2.5 cm palpable left supraclavicular node that on excisional biopsy demonstrated metastatic endometrial adenocarcinoma. Due to the advanced stage of her cancer as well as the presence of multiple metastases, including lung and hepatic metastases causing post-obstructive pneumonia and coagulopathy, the sellar/suprasellar mass was treated with fractionated radiosurgery rather than surgical excision.

[1]  Wesley H. Stepp,et al.  Clinical characteristics of CNS metastases from primary gynecologic cancers☆ , 2019, Gynecologic oncology reports.

[2]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial , 2019, The Lancet. Oncology.

[3]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[4]  V. Sawlani,et al.  The Expanding Role of Radiosurgery for Brain Metastases , 2018, Medicines.

[5]  R. Fonti,et al.  Metastasis to the Sellar/Suprasellar Region in a Patient With Endometrial Carcinoma Detected by 18F-FDG PET/CT. , 2018, Clinical nuclear medicine.

[6]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[8]  S. Temkin,et al.  Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. , 2016, Gynecologic oncology.

[9]  J. Wilczyński,et al.  The significance of markers in the diagnosis of endometrial cancer , 2016, Przeglad menopauzalny = Menopause review.

[10]  G. Fleming,et al.  Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. , 2016, The oncologist.

[11]  Jonathan M. Morris,et al.  Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature. , 2016, Gynecologic oncology.

[12]  G. Fleming.  Second-Line Therapy for Endometrial Cancer: The Need for Better Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Muggia,et al.  Targeting HER2 in ovarian and uterine cancers: challenges and future directions. , 2014, Gynecologic oncology.

[14]  J. Rockhill,et al.  Stereotactic radiosurgery and stereotactic radiotherapy for brain metastases , 2013, Surgical neurology international.

[15]  J. Jagannathan,et al.  Typical and atypical metastatic sites of recurrent endometrial carcinoma , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[16]  R. Barakat,et al.  Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Berek,et al.  Phase II Trial of Trastuzumab in Women with Advanced or Recurrent , HER 2-Positive Endometrial Carcinoma : a Gynecologic Oncology Group Study , 2010 .

[18]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[19]  O. Olopade,et al.  An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[20]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[21]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[22]  D. Zagzag,et al.  Endometrial Carcinoma with Cerebellar Metastasis: A Case Report and Review of the Literature , 2002, Journal of Neuro-Oncology.